Liver TransplantationNCT07728604
Effect of Digital Follow-up Supported Patient Education on Immunosuppressive Medication Adherence and Quality of Life After Liver Transplantation
A study testing Digital Follow-up Supported Patient Education in people with Liver Transplantation and Medication Adherence, run by Cansu Yıldız at 1 site in Turkey (Türkiye).
Trial summary
This randomized controlled study aimed to evaluate the effect of digital follow-up supported patient education on immunosuppressive medication adherence and quality of life in adult liver transplant recipients. Participants in both groups received standard discharge education. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Liver Transplantation, Medication Adherence
- What is being tested?
- Digital Follow-up Supported Patient Education
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 23 Jan 2026to 20 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older.
- Having undergone liver transplantation.
- Currently receiving immunosuppressive therapy after liver transplantation.
- Ability to read and write in Turkish.
- Ability to use a smartphone to receive and follow digital messages.
- Willingness to participate voluntarily in the study.
- Provision of written informed consent.
Who cannot join
- Experiencing an acute rejection episode during the study period.
- Presence of cognitive, psychiatric, or communication problems that would interfere with participation in the study.
- Inability to regularly follow digital messages.
- Difficulty reading and understanding Turkish.
- Inability to maintain communication throughout the study period.
- Refusal to participate in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Digital Follow-up Supported Patient Education on Immunosuppressive Medication Adherence and Quality of Life in Liver Transplant Recipients: A Single-Blind Randomized Controlled Trial.
This randomized controlled study aimed to evaluate the effect of digital follow-up supported patient education on immunosuppressive medication adherence and quality of life in adult liver transplant recipients. Participants in both groups received standard discharge education. The intervention group additionally received structured digital follow-up messages for 12 weeks, while the control group received standard care only. Medication adherence and quality of life were assessed before and after the intervention using validated questionnaires.
Read the detailed description
Lifelong adherence to immunosuppressive medication is essential for preventing graft rejection and maintaining long-term graft survival after liver transplantation. However, medication non-adherence remains a common problem and may negatively affect patient outcomes and quality of life. Digital follow-up interventions may improve adherence by providing regular reminders and educational support after discharge.
This single-blind randomized controlled trial was conducted at the Liver Transplant Center of Acibadem Kent Hospital, İzmir, Türkiye. Adult liver transplant recipients who met the eligibility criteria were randomly assigned to either a digital education group or a control group. All participants received standard discharge education. In addition, participants in the intervention group received structured digital follow-up messages for 12 weeks. The control group received routine follow-up care only.
The primary outcome was immunosuppressive medication adherence, assessed using the Immunosuppressive Medication Adherence Scale (MMAS-8). The secondary outcome was quality of life, assessed using the Chronic Liver Disease Questionnaire (CLDQ 2.0). Outcomes were evaluated before the intervention and at the end of the 12-week follow-up period.
- Conditions
- Liver Transplantation, Medication Adherence
- Being tested
- Digital Follow-up Supported Patient Education, Standard Care
- Keywords
- Liver transplantation, Immunosuppressive medication, Medication adherence, Digital patient education, Digital follow-up, Quality of life, Randomized controlled trial, Nursing intervention
- Medical subject headings
- Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital Follow-up Supported Patient EducationBehavioural
Participants received standard discharge education followed by structured digital follow-up messages for 12 weeks to improve immunosuppressive medication adherence and quality of life.
Standard CareOther
Participants received routine discharge education and standard follow-up care. No additional digital follow-up messages or educational reminders were provided during the study period.
| Study group | Role | What they receive |
|---|---|---|
| Digital Education Group | Experimental | Participants received standard discharge education plus structured digital follow-up messages for 12 weeks to improve immunosuppressive medication adherence and quality of life. Receives: Behavioral: Digital Follow-up Supported Patient Education |
| Control Group | Active comparator | articipants received standard discharge education and routine follow-up care without additional digital follow-up messages. Receives: Other: Standard Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Immunosuppressive Medication Adherence
Immunosuppressive medication adherence was assessed using the Immunosuppressive Medication Adherence Scale used in this study.
Measured: Baseline and 12 weeks
Secondary outcomes (1)
Chronic Liver Disease Quality of Life Score (CLDQ 2.0)
Quality of life was assessed using the Chronic Liver Disease Questionnaire (CLDQ 2.0).
Measured: Baseline and 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jul 2026
- Study start23 Jan 2026
- Primary completion20 Jun 2026
- Study completion20 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cansu Yıldız
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Cansu Yıldız, Izmir Tinaztepe University
- Investigators
- Cansu Yıldız, Principal investigator, İzmir Tınaztepe University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07728604
- Sponsor's protocol ID
- TYU-LT-2026-001
- Status last verified
- Jan 2026
- First submitted
- 22 Jul 2026
- Last updated
- 27 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to participant confidentiality and institutional policies.
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Digital Follow-up Supported Patient Education on Immunosuppressive Medication Adherence and Quality of Life in Liver Transplant Recipients: A Single-Blind Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT07728604
- Acronym / sponsor ID
- TYU-LT-2026-001
- Conditions
- Liver Transplantation, Medication Adherence
- Keywords
- Liver transplantation, Immunosuppressive medication, Medication adherence, Digital patient education, Digital follow-up, Quality of life, Randomized controlled trial, Nursing intervention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Cansu YıldızUniversity, hospital or other
- Study start
- 23 Jan 2026 (actual)
- Primary completion
- 20 Jun 2026 (actual)
- Study completion
- 20 Jun 2026 (actual)
- First posted
- 27 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled study aimed to evaluate the effect of digital follow-up supported patient education on immunosuppressive medication adherence and quality of life in adult liver transplant recipients. Participants in both groups received standard discharge education. The intervention group additionally received structured digital follow-up messages for 12 weeks, while the control group received standard care only. Medication adherence and quality of life were assessed before and after the intervention using validated questionnaires.
Detailed description
Lifelong adherence to immunosuppressive medication is essential for preventing graft rejection and maintaining long-term graft survival after liver transplantation. However, medication non-adherence remains a common problem and may negatively affect patient outcomes and quality of life. Digital follow-up interventions may improve adherence by providing regular reminders and educational support after discharge.
This single-blind randomized controlled trial was conducted at the Liver Transplant Center of Acibadem Kent Hospital, İzmir, Türkiye. Adult liver transplant recipients who met the eligibility criteria were randomly assigned to either a digital education group or a control group. All participants received standard discharge education. In addition, participants in the intervention group received structured digital follow-up messages for 12 weeks. The control group received routine follow-up care only.
The primary outcome was immunosuppressive medication adherence, assessed using the Immunosuppressive Medication Adherence Scale (MMAS-8). The secondary outcome was quality of life, assessed using the Chronic Liver Disease Questionnaire (CLDQ 2.0). Outcomes were evaluated before the intervention and at the end of the 12-week follow-up period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Digital Education Group | Experimental | Behavioral: Digital Follow-up Supported Patient EducationParticipants received standard discharge education plus structured digital follow-up messages for 12 weeks to improve immunosuppressive medication adherence and quality of life. |
| Control Group | Active comparator | Other: Standard Carearticipants received standard discharge education and routine follow-up care without additional digital follow-up messages. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age 18 years or older.
- Having undergone liver transplantation.
- Currently receiving immunosuppressive therapy after liver transplantation.
- Ability to read and write in Turkish.
- Ability to use a smartphone to receive and follow digital messages.
Key exclusion criteria (6 listed)
- Experiencing an acute rejection episode during the study period.
- Presence of cognitive, psychiatric, or communication problems that would interfere with participation in the study.
- Inability to regularly follow digital messages.
- Difficulty reading and understanding Turkish.
- Inability to maintain communication throughout the study period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital Follow-up Supported Patient EducationParticipants received standard discharge education followed by structured digital follow-up messages for 12 weeks to improve immunosuppressive medication adherence and quality of life. | Behavioural | Digital Education Group |
| Standard CareParticipants received routine discharge education and standard follow-up care. No additional digital follow-up messages or educational reminders were provided during the study period. | Other | Control Group |
Primary outcome
Immunosuppressive Medication Adherence
Time frame: Baseline and 12 weeks
Immunosuppressive medication adherence was assessed using the Immunosuppressive Medication Adherence Scale used in this study.
1 secondary outcome
Chronic Liver Disease Quality of Life Score (CLDQ 2.0)
Time frame: Baseline and 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to participant confidentiality and institutional policies.
Related trials for Liver Transplantation
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
RecruitingPhase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Liver Transplant
RecruitingObservational study
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cansu Yıldız principal investigator
İzmir Tınaztepe University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital Follow-up Supported Patient Education in people with Liver Transplantation and Medication Adherence, run by Cansu Yıldız at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Immunosuppressive Medication Adherence (time frame: Baseline and 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.